Language

English

Publication Date

1-8-2024

Journal

Cancer Cell

DOI

10.1016/j.ccell.2023.11.002

PMID

38039965

PMCID

PMC11067690

PubMedCentral® Posted Date

1-8-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.

Keywords

Humans, Child, Brain Neoplasms, Glioma, Mutation, Brain, Biopsy

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.